The notice, registration form and power of attorney are attached to this
release. The notice will be sent to all registered shareholders and is available
Due to COVID-19 related restrictions and the advice from the Norwegian
government all shareholders are encouraged to exercise their shareholder rights
without physical attendance at the general meeting, either through advance
electronically voting through VPS Investor Services or by using the enclosed
proxy form to provide proxy to the Chairman Sveinung Hole (or the person he
Notice of attendance, advance vote or proxy for the Extraordinary General
Meeting can be registered through the company’s website or VPS Investor Service.
All registered shareholders will receive a reference number and a pin code
required for registration through the company’s website. Reference number and
pin code will be received either by VPS Investor Service or by post depending if
the shareholder is registered as electronical user.
We encourage all shareholders to register as electronical user in VPS to save
Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie, CFO, BerGenBio ASA
+47 917 86 513
BerGenBio is a clinical-stage biopharmaceutical company focused on
developing transformative drugs targeting AXL as a potential cornerstone of
therapy for aggressive diseases, including immune-evasive, therapy resistant
cancers and infectious diseases. The company’s proprietary lead candidate,
bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad
Phase II oncology clinical development programme focused on combination and
single agent therapyin lung cancer and leukaemia. A first-in-class functional
blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing.
In parallel,BerGenBio is developing companion diagnostic tests to identify those
patient populations most likely to benefit from bemcentinib: this is expected
to facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For
more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.